Stay updated with breaking news from Nasdaq fwbi. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
First Wave BioPharma, Inc. (NASDAQ:FWBI – Get Free Report) saw a large increase in short interest in the month of January. As of January 31st, there was short interest totalling 176,600 shares, an increase of 39.7% from the January 15th total of 126,400 shares. Approximately 28.7% of the company’s stock are sold short. Based on […] ....
First Wave BioPharma, Inc. (NASDAQ:FWBI – Get Free Report) traded down 3% during mid-day trading on Thursday . The stock traded as low as $4.95 and last traded at $5.14. 159,133 shares changed hands during trading, a decline of 75% from the average session volume of 644,631 shares. The stock had previously closed at $5.30. […] ....
First Wave BioPharma (NASDAQ:FWBI – Free Report) had its price target upped by Roth Mkm to $40.00 in a research report report published on Wednesday, Benzinga reports. Roth Mkm currently has a buy rating on the stock. First Wave BioPharma Trading Up 2.4 % NASDAQ FWBI opened at $5.57 on Wednesday. First Wave BioPharma has […] ....
BOCA RATON, Fla., Dec. 27, 2023 (GLOBE NEWSWIRE) First Wave BioPharma, Inc. (“First Wave BioPharma” or the “Company”) (NASDAQ: FWBI), a clinical-stage. ....
First Wave BioPharma to advance GI development pipeline with the expected addition of Phase 3 Latiglutenase celiac disease program and Phase 2 clinical. ....